These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31712951)

  • 21. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
    Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
    Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
    van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis.
    Paredes AZ; Guzman-Pruneda FA; Abdel-Misih S; Hays J; Dillhoff ME; Pawlik TM; Cloyd JM
    J Surg Res; 2019 Sep; 241():31-39. PubMed ID: 31004870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does Intraoperative Systematic Bacterial Sampling During Complete Cytoreductive Surgery (CRS) with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) Influence Postoperative Treatment? A New Predictive Factor for Postoperative Abdominal Infectious Complications.
    Dazza M; Schwarz L; Coget J; Frebourg N; Wood G; Huet E; Bridoux V; Veber B; Tuech JJ
    World J Surg; 2016 Dec; 40(12):3035-3043. PubMed ID: 27412631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperthermic intraperitoneal chemotherapy does not increase risk of major complication or failure to rescue in cytoreductive surgery.
    Macfie RC; Cha DE; Gleeson E; Yu A; Cohen N; Sarpel U; Golas B; Hiotis S; Labow D
    J Surg Oncol; 2022 Sep; 126(4):781-786. PubMed ID: 35668645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients: Complete Cytoreduction Is Feasible and Crucial for Improved Survival Despite High Carcinomatosis Index.
    Naffouje SA; Salti GI
    Anticancer Res; 2018 Jan; 38(1):441-448. PubMed ID: 29277807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The perioperative safety of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):419-424. PubMed ID: 32482033
    [No Abstract]   [Full Text] [Related]  

  • 29. Anaesthetic management of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective audit.
    Shiralkar SP; Kerr P; Scott J; Sivalingam P
    Anaesth Intensive Care; 2017 Jul; 45(4):490-498. PubMed ID: 28673220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased Incidence of Central Venous Catheter-Related Infection in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy.
    Waters PS; Smith AW; Fitzgerald E; Khan F; Moran BJ; Shields CJ; Lynch BL; O'Loughlin C; Lynch M; Mulsow J
    Surg Infect (Larchmt); 2019 Sep; 20(6):465-471. PubMed ID: 31013189
    [No Abstract]   [Full Text] [Related]  

  • 31. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.
    Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.
    Hallam S; Tyler R; Price M; Beggs A; Youssef H
    BJS Open; 2019 Oct; 3(5):585-594. PubMed ID: 31592510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases.
    Narasimhan V; Das A; Warrier S; Lynch C; McCormick J; Tie J; Michael M; Ramsay R; Heriot A
    Langenbecks Arch Surg; 2019 Aug; 404(5):527-539. PubMed ID: 31377856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Tan JW; Tan GHC; Ng WY; Ong CJ; Chia CS; Soo KC; Teo MCC
    Int J Clin Oncol; 2020 May; 25(5):984-994. PubMed ID: 31915944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoreduction and hyperthermic intraperitoneal chemotherapy: The learning curve reassessed.
    Kuijpers AM; Hauptmann M; Aalbers AG; Nienhuijs SW; de Hingh IH; Wiezer MJ; van Ramshorst B; van Ginkel RJ; Havenga K; Verwaal VJ
    Eur J Surg Oncol; 2016 Feb; 42(2):244-50. PubMed ID: 26375923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies.
    Dreznik Y; Hoffman A; Hamburger T; Ben-Yaacov A; Dux Y; Jacoby H; Berger Y; Nissan A; Gutman M
    Surgeon; 2018 Oct; 16(5):278-282. PubMed ID: 29429947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
    Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G
    Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of serial debulking and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei of appendiceal origin.
    Järvinen P; Ristimäki A; Kantonen J; Aronen M; Huuhtanen R; Järvinen H; Lepistö A
    Int J Colorectal Dis; 2014 Aug; 29(8):999-1007. PubMed ID: 24965858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.